Amylin signs weight-loss drug deal with Takeda
NEW YORK — Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan’s Takeda Pharmaceutical Co. on potential weight-loss treatments.
Company shares climbed nearly 10 percent in trading Monday, despite an announcement that government regulators strengthened warning labels on company’s diabetes treatment Byetta.
The Food and Drug Administration highlighted bolstered language about kidney damage on the drug’s labeling.
Amylin, based in San Diego, said late Sunday it will receive $75 million upfront from Takeda and said future payments for development and achieving commercial milestones could top $1 billion.
The deal includes two potential weight-loss treatments, a pramlintide-metreleptin combination and davalintide. Both potential drugs are in midstage, or Phase II, clinical development. In July, Amylin said pramlintide-metreleptin prompted an average weight loss of 22 pounds, or 11 percent of patients’ body weight, during a midstage study.
The deal also includes additional compounds from both companies research programs. Aside from milestone payments, Amylin is also eligible for royalties on global sales.
Its shares rose $1.09, or 9.9 percent, to close at $12.13 Monday.
Amylin is responsible for developing potential products through midstage development, while Takeda will take over late-stage development, along with all development activities outside the U.S.
Amylin estimates it will be responsible for 20 percent of development costs for obtaining approval for products in the U.S.
Leerink Swann Research analyst Dr. Joshua Schimmer reaffirmed a “Market Perform” rating for Amylin, saying the obesity drug deal will help reduce future expenses. He said Amylin costs for obesity drugs represented about 13 percent of second-quarter research and development costs.
On Friday, Amylin said the FDA expanded approval of Byetta as a stand-alone diabetes treatment. Previously, it was approved for use in combination with other diabetes drugs.
Schimmer said there will likely be little change in how physicians prescribe Byetta following the expanded approval, saying doctors have already been prescribing the drug off-label as a stand-alone therapy.
The FDA also strengthened warning language on Byetta, following more than 60 reports of kidney failure with the drug between April 2005 and October 2008.
While the previous label mentioned such side effects, the new language specifies that doctors should not prescribe Byetta to patients with severe kidney problems. The FDA did not put the warning in a so-called “black box,” a move that could have raised safety concerns among doctors.
“In our view these developments are in line with expectations and we do not expect any impact to Byetta sales as pancreatitis was first added as a precaution on the label in October 2007,” wrote Lazard Capital Markets analyst Michael O’Brien, in a note to investors.
The Amylin-Takeda deal comes amid a surge in obesity treatment research and development from the biotechnology industry. Several companies already have their potential drugs in late-stage development, setting the stage for a competitive market if each gains Food and Drug Administration approval.
In October, several companies reported positive updates to their studies at the annual scientific meeting of The Obesity Society in Washington DC.
Vivus Inc. said patients taking its potential weight-loss drug Qnexa lost about 11 percent of their body weight. Arena Pharmaceuticals Inc. said patients taking lorcaserin lost 31 percent of their excess body weight in the first year of a two-year study. Earlier this year, Orexigen Therapeutics Inc. reported results showing that Contrave patients lost more than 8 percent of their weight.
Related News
Amylin Pharmaceuticals signs obesity drug deal with Takeda potentially worth over $1 billionNovember 2nd, 2009 more images
more images
Amylin signs obesity drug deal with Takeda
NEW YORK — Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co.
Revolutionary once-a-day fat-busting jab may help beat obesityOctober 23rd, 2009 LONDON - Scientists have created a revolutionary once-a-day jab that can fight obesity. Liraglutide not only controls the symptoms of diabetes but also leads to significant weight loss.
Dairy foods 'help fight the flab'October 21st, 2009 SYDNEY - Higher intake of dairy products while on a reduced calorie diet can help help fight obesity, say researchers. During the study, lead researcher Wendy Chan She Ping Delfos, from Curtin University of Technology, compared three serves of dairy food such as yoghurt, cheese and low fat milk, with five serves within a lower calorie diet prescribed to overweight participants over 12-weeks.
Onyx will acquire Proteolix and its blood cancer drug candidate in deal worth up to $851MOctober 12th, 2009 Onyx Pharma will pay up to $851M for ProteolixNEW YORK — Onyx Pharmaceuticals Inc. said Monday it will buy cancer drug developer Proteolix Inc.
Novartis to pay up to $485M for rights to US firm's antibiotic for drug-resistant bacteriaOctober 8th, 2009 Novartis buys rights to next-generation antibioticBASEL, Switzerland — Novartis AG said Thursday it has bought worldwide rights to a new antibiotic drug developed by U.S. company Paratek Pharmaceuticals to treat drug-resistant bacteria such as MRSA.
Novartis says it licensed oral and IV treatment for infections from drug-resistant bacteriaOctober 8th, 2009 Novartis gets worldwide rights to antibioticNEW YORK — Swiss drugmaker Novartis AG said Thursday it bought worldwide marketing rights to an antibiotic that is being developed to treat infections caused by drug-resistant bacteria, potentially including the "superbug" MRSA. Novartis did not disclose the payments it will make to the drug's developer, Paratek Pharmaceuticals of Boston.
Lupin buys anti-cholesterol drug rights for $39 mnSeptember 28th, 2009 MUMBAI - Indian pharmaceuticals major Lupin Tuesday said it had acquired the rights for Antara, a drug to treat high blood cholesterol and high triglycerides, for $38.61 million from the US-based Oscient Pharmaceuticals. The rights for the drug, along with related assets and inventories, have been acquired under the procedures of the US Bankruptcy Court, the company said in a regulatory filing with the Bombay Stock Exchange (BSE).
Being too optimistic could harm weight loss effortsSeptember 25th, 2009 WASHINGTON - Being too optimistic or self-oriented might stop you from losing weight, finds a new study. The researchers from Doshisha University, Japan have found that personality traits have a significant impact on weight loss efforts.
Arena diet drug lorcaserin succeeds in trial, but comes up short of competing drug candidatesSeptember 18th, 2009 Arena obesity drug falls short against other medsNEW YORK — Arena Pharmaceuticals Inc. said on Friday that its obesity drug candidate lorcaserin succeeded in a clinical study, but the drug did not appear to be as effective as other treatments competitors have in development.
Weight loss can prevent kidney disease progression in obese patientsSeptember 18th, 2009 WASHINGTON - Shedding extra pounds can preserve kidney function in obese people with kidney disease, according to a new study led by Indian origin scientist from Cleveland Clinic. Weight loss can improve a number of health problems, like it can improve control of diabetes, lower blood pressure and cholesterol levels, and reduce the effects of heart disease.
How some people maintain weight loss, others don'tSeptember 16th, 2009 WASHINGTON - Ever wondered how some people successfully maintain a significant weight loss, while others tend to regain the weight? Well, researchers at The Miriam Hospital attribute such tendencies to a difference in brain activity patterns. The researchers showed that when individuals who had kept the weight off for several years were shown pictures of food, they were more likely to engage the areas of the brain associated with behavioural control and visual attention, as compared to obese and normal weight participants.
NJ pharmaceuticals firm Biovail to pay nearly $25M after guilty plea in doctor kickbacks caseSeptember 14th, 2009 NJ drug firm to pay nearly $25M in kickbacks caseBOSTON — A New Jersey pharmaceuticals firm will pay nearly $25 million in criminal and civil fines after pleading guilty to federal charges that it made illegal payments to encourage doctors to prescribe a blood pressure drug. The U.S. attorney's office in Boston announced Monday that Bridgewater-based Biovail Pharmaceuticals Inc.
NxStage Medical signs 3-year deal to supply Reliant Renal Care with dialysis productsSeptember 14th, 2009 NxStage Medical signs 3-year supply dealLAWRENCE, Mass. — Medical device maker NxStage Medical Inc.
Indiana court says employer must pay for weight-loss surgery for worker with injured backSeptember 10th, 2009 Court: Employer must pay for weight-loss surgeryINDIANAPOLIS — The Indiana Court of Appeals has ruled that a pizza shop must pay for weight-loss surgery for an obese employee to ensure the success of another operation for a back injury he suffered at work. The decision is raising concern among businesses bracing for more such claims.
Watson Pharmaceuticals gets FDA approval for over-the-counter emergency contraceptiveAugust 28th, 2009 Watson gets approval for emergency contraceptiveCORONA, Calif. — Watson Pharmaceuticals Inc.
